Look­ing for fresh start fol­low­ing a Duchenne dis­as­ter, Cataba­sis re­brands; Huadong and In­sil­i­co team up in on­col­o­gy

The lead­ers of Cataba­sis Phar­ma­ceu­ti­cals have de­creed that the biotech’s name is no more. Cataba­sis will be re­brand­ing to As­tria Ther­a­peu­tics ef­fec­tive im­me­di­ate­ly, with the com­pa­ny’s stock tick­er be­ing up­dat­ed on the Nas­daq on Thurs­day.

As­tria will drop the $CATB tick­er and trade un­der $ATXS.

The biotech is al­so re­nam­ing its lead com­pound from QLS-215 to STAR-0215, cur­rent­ly in pre­clin­i­cal de­vel­op­ment for the rare ge­net­ic dis­ease called hered­i­tary an­gioede­ma. As­tria ac­quired the pro­gram in its buy­out of Quel­lis Bio­sciences back in Jan­u­ary. That deal fol­lowed the com­plete col­lapse of their long-run­ning Duchenne MD drug, which flunked a Phase III tri­al last Oc­to­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER